Keyphrases
Hemodialysis Patients
86%
Arteriovenous Fistula
46%
Hemodialysis
45%
Far-infrared Therapy
41%
Peritoneal Dialysis
34%
Vascular Access
29%
Taiwan
27%
Maintenance Hemodialysis Patients
26%
Peritoneal Dialysis Patients
23%
Chronic Kidney Disease
23%
Patency
22%
Uremic Patients
22%
Hazard Ratio
17%
Dialysis
17%
Heme oxygenase-1 (HO-1)
16%
Fistula Patency
14%
Risk Factors
14%
Confidence Interval
14%
Hemodialysis Vascular Access
14%
Arteriovenous Graft
13%
National Cohort Study
13%
South-East Asia
13%
Asymmetric Dimethylarginine
13%
Continuous Erythropoietin Receptor Activator
12%
Randomized Controlled Trial
11%
End-stage Renal Disease
11%
Perfluorohexanoic Acid (PFHxA)
11%
Continuous Ambulatory Peritoneal Dialysis
11%
Proteinuria
10%
Dialysis Membrane
10%
Hematocrit
10%
South Asia
10%
Erythropoiesis-stimulating Agents
10%
Clinical Outcomes
10%
Genotype Polymorphism
10%
Genotype
9%
End-stage Kidney Disease
9%
Diabetic Nephropathy
9%
Diabetes
9%
High Risk
9%
Far-infrared
9%
Yoga
8%
Dialysis Access
8%
Angiotensin Receptor Blockers
8%
Dialysis Patients
8%
Hypoglycemia
8%
Protein-to-creatinine Ratio
8%
Diabetic Kidney Disease
8%
Epidemiology
7%
Vascular Thrombosis
7%
Medicine and Dentistry
Hemodialysis
81%
Peritoneal Dialysis
41%
Vascular Access
27%
End Stage Renal Disease
24%
Chronic Kidney Disease
24%
Heat Therapy
23%
Arteriovenous Fistula
21%
Diabetic Nephropathy
18%
Randomized Controlled Trial
13%
Nephropathy
12%
Diabetes Mellitus
11%
Cohort Analysis
11%
Diabetes
11%
Hazard Ratio
10%
Prevalence
10%
N(g),n(g) Dimethylarginine
9%
Nephrology
8%
Blood Pressure
8%
Apoplexy
8%
Glomerulonephritis
8%
Cohort Effect
7%
Continuous Ambulatory Peritoneal Dialysis
7%
Prognostic Factor
7%
Patient with Diabetes
7%
Podocyte
6%
Yoga
6%
Peritonitis
6%
Ankle Brachial Index
6%
Canagliflozin
6%
Hypoglycemia
6%
Coronavirinae
6%
Meta-Analysis
6%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Pneumocystis Pneumonia
6%
Clinical Trial
6%
Kidney Function
6%
Dialysis Catheter
6%
Cardiovascular System
6%
Hematocrit
6%
Continuous Erythropoiesis Receptor Activator
5%
Bleeding
5%
Immunosuppressive Drug
5%
Analeptic
5%
Nutritional Status
5%
Health Care Cost
5%
Therapeutic Modality
5%
Acute Kidney Injury
5%
Infection
5%
Quality of Life
5%
Pharmacology, Toxicology and Pharmaceutical Science
Hemodialysis
100%
Arteriovenous Fistula
41%
End Stage Renal Disease
20%
Diabetic Nephropathy
19%
Chronic Kidney Failure
19%
Randomized Controlled Trial
17%
Cohort Study
16%
Inflammation
13%
Kidney Disease
13%
6 N,n' Dimethylarginine
13%
N(g),n(g) Dimethylarginine
13%
Heme Oxygenase 1
11%
Creatinine
10%
Coronavirinae
10%
Continuous Erythropoiesis Receptor Activator
9%
Disease
9%
Perfluorooctanesulfonic Acid
8%
Diabetes Mellitus
8%
Angiotensin Receptor Antagonist
8%
Non Insulin Dependent Diabetes Mellitus
8%
Hypoglycemia
8%
Acute Kidney Failure
8%
Dipeptidyl Carboxypeptidase Inhibitor
7%
C Reactive Protein
7%
Cardiovascular Disease
7%
Acrolein
6%
Peritonitis
6%
Canagliflozin
6%
Dipeptidyl Peptidase IV Inhibitor
6%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Atrial Fibrillation
6%
Clinical Trial
6%
Kidney Fibrosis
6%
Perfluoro Compound
6%
Heart Failure
6%
Perfluorooctanoic Acid
5%
Infection
5%
Polysulfone
5%
Retrospective Study
5%
Brain Ischemia
5%
Angiotensin
5%
Renin
5%
Anemia
5%
SARS Coronavirus
5%
Glucose Degradation Product
5%
